A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE | MicrobiomeTrials← Back to trialsNCT06897930
A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2025-04-21Est. Completion: 2029-05-01
Enrollment target: 150 participants Locations- Research Site, San Francisco, California, United States
- Research Site, Stanford, California, United States
- Research Site, Tampa, Florida, United States
- Research Site, Atlanta, Georgia, United States
- Research Site, Chicago, Illinois, United States
- Research Site, Bethesda, Maryland, United States
- Research Site, Boston, Massachusetts, United States
- Research Site, St Louis, Missouri, United States
- Research Site, New York, New York, United States
- Research Site, Syracuse, New York, United States
- Research Site, Chapel Hill, North Carolina, United States
- Research Site, Charlotte, North Carolina, United States
- Research Site, Richmond, Virginia, United States
- Research Site, Seattle, Washington, United States
- Research Site, Seattle, Washington, United States
- Research Site, Darlinghurst, Australia
- Research Site, Melbourne, Australia
- Research Site, Toronto, Canada
Other microbiome trials you might be interested in
Autoimmune Diseases
Background:
Autoimmune diseases can be caused by genes people inherit from their parents. The gene changes that cause t…
Bethesda, United StatesEst. completion Apr 22, 2030
Rheumatoid Arthritis (RA)Systemic Lupus Erythematosus (SLE)Pemphigus VulgarisMultiple Sclerosis (MS)Systemic Sclerosis (SSc)Pediatric SLEJuvenile Idiopathic Arthritis (JIA)Juvenile Dermatomyositis (JDM)Pediatric-Onset Multiple Sclerosis (POMS)
This is a randomized, multi-site, adaptive, open-label clinical trial comparing the immune response to different additio…
Los Angeles, United StatesCompleted Jun 22, 2023